What it's for (Indications)
- Fluconazole is a triazole antifungal agent indicated for the treatment and prophylaxis of a wide range of fungal infections, primarily caused by *Candida* species and *Cryptococcus neoformans*.
- Its primary indications include the treatment of oropharyngeal and esophageal candidiasis, particularly in immunocompromised patients, such as those with HIV/AIDS or undergoing chemotherapy.
- It is also highly effective for the treatment of acute vaginal candidiasis, often as a single oral dose.
- Furthermore, fluconazole is approved for systemic candidiasis, which encompasses candidemia, disseminated candidiasis, and other severe forms of invasive candidal infections affecting various organs including the peritoneum, endocardium, and urinary tract.
- A critical indication is the treatment of cryptococcal meningitis, and its use for prophylaxis to prevent relapse of cryptococcal disease in patients with AIDS is well-established.
- Additionally, it is used for the prophylaxis of candidiasis in patients undergoing bone marrow transplantation who are at high risk due to cytotoxic chemotherapy and/or radiation therapy.
- This broad spectrum of activity against common pathogenic fungi makes fluconazole a cornerstone in antifungal therapy for both superficial and deep-seated infections, particularly when an oral or intravenous systemic antifungal is required.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of fluconazole is highly individualized and depends significantly on the specific fungal infection being treated, the patient's age, weight, renal function, and immune status. For acute vaginal candidiasis, a single oral dose of 150 mg is typically administered. For oropharyngeal candidiasis, common regimens involve a loading dose of 200 mg on the first day followed by 100 mg once daily for at least 2 weeks. Esophageal candidiasis often requires 200 mg to 400 mg on the first day, followed by 100 mg to 200 mg daily for at least 3 weeks and for at least 2 weeks after symptom resolution. Systemic candidiasis and cryptococcal meningitis generally necessitate higher doses, often starting with a loading dose of 400 mg on the first day, followed by 200 mg to 400 mg daily. In severe cases, daily doses up to 800 mg may be required. For prophylaxis of candidiasis in bone marrow transplant patients, 400 mg once daily is common. Pediatric dosages are calculated based on body weight, typically ranging from 3 mg/kg to 12 mg/kg per day, depending on the indication. Dosage adjustments are crucial in patients with impaired renal function, based on creatinine clearance, to prevent accumulation and potential toxicity. It is imperative to consult current guidelines and a healthcare professional for precise dosing recommendations, as inappropriate dosing can lead to treatment failure or increased adverse events. |
Safety & Warnings
Common Side Effects
- Fluconazole is generally well-tolerated, but like all medications, it can cause a range of side effects, varying in severity and incidence.
- Common adverse reactions, typically mild and transient, include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea.
- Headaches are also frequently reported.
- Skin rashes are another common occurrence, which are usually mild but warrant monitoring.
- More serious, albeit less frequent, side effects include significant hepatotoxicity, characterized by elevated liver enzyme levels, jaundice, and in rare cases, severe liver injury, requiring immediate discontinuation.
- Cardiovascular effects, particularly prolongation of the QT interval and Torsades de Pointes, are a concern, especially in patients with pre-existing cardiac conditions or those on other QT-prolonging medications.
- Severe dermatologic reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are rare but life-threatening hypersensitivity reactions.
- Anaphylaxis and angioedema are also possible, indicating an allergic response.
- Other potential adverse events include adrenal insufficiency, alopecia (especially with prolonged high-dose therapy), and taste perversion.
- Patients should be advised to seek prompt medical attention for persistent, worsening, or severe symptoms, particularly skin rashes, signs of liver problems, or heart palpitations.
Serious Warnings
- Black Box Warning: **Serious Warnings** Fluconazole does not carry a formal Black Box Warning from the U.S. Food and Drug Administration (FDA). However, it is associated with several serious potential adverse effects that warrant careful consideration and vigilant monitoring during therapy by healthcare professionals and patients. Healthcare providers and patients should be acutely aware of the following high-risk factors that could lead to severe outcomes: 1. **Hepatotoxicity**: Fluconazole has been associated with rare but severe cases of hepatotoxicity, ranging from transient elevations in liver enzymes to cholestasis, hepatitis, and hepatic necrosis, sometimes resulting in fatal outcomes. Patients should be closely monitored for clinical signs and symptoms of liver dysfunction (e.g., jaundice, dark urine, persistent nausea, vomiting, abdominal pain, fatigue). Liver function tests (e.g., AST, ALT, alkaline phosphatase, bilirubin) should be regularly assessed, especially in patients with pre-existing liver disease, those on prolonged treatment regimens, or those concurrently taking other hepatotoxic medications. Fluconazole should be promptly discontinued if clinical signs and symptoms consistent with liver disease develop, or if liver function tests become significantly abnormal. 2. **Cardiovascular Effects**: Fluconazole can cause prolongation of the QT interval on an electrocardiogram, which increases the risk of serious ventricular arrhythmias, including life-threatening Torsades de Pointes. This risk is particularly elevated in patients with multiple pre-existing risk factors, such as structural cardiac disease, history of arrhythmias, uncorrected electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), and concomitant use of other medications known to prolong the QT interval (e.g., amiodarone, quinidine, certain antipsychotics). Extreme caution is advised in these patient populations, and ECG monitoring, along with electrolyte correction, may be necessary prior to and during fluconazole therapy. 3. **Severe Dermatologic Reactions**: Rare cases of serious exfoliative cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported during fluconazole treatment. These reactions can be severe and life-threatening. If a patient develops a rash during fluconazole therapy, they should be closely monitored. Fluconazole should be discontinued immediately if the rash progresses, if lesions suggestive of SJS/TEN develop, or if the rash is associated with systemic symptoms such as fever, lymphadenopathy, facial swelling, or eosinophilia. Patients with AIDS appear to be more prone to severe skin reactions with many drugs, including fluconazole.
- Several critical warnings and precautions are associated with fluconazole therapy, necessitating careful patient evaluation and monitoring.
- Hepatotoxicity, ranging from transient enzyme elevations to rare but fatal hepatic necrosis, has been reported; therefore, liver function tests should be monitored, especially in patients with pre-existing hepatic impairment, those on prolonged therapy, or those concurrently taking other hepatotoxic drugs.
- Fluconazole can prolong the QT interval on an electrocardiogram, increasing the risk of serious ventricular arrhythmias like Torsades de Pointes.
- This risk is elevated in patients with electrolyte imbalances (e.
- g.
- , hypokalemia, hypomagnesemia), existing cardiac disease, or concomitant use of other QT-prolonging drugs; caution and ECG monitoring are advised in such high-risk individuals.
- Severe cutaneous adverse reactions, including exfoliative skin disorders such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred, necessitating immediate discontinuation at the first sign of a severe or widespread rash.
- Adrenal insufficiency has been observed, particularly with prolonged fluconazole therapy, and patients should be monitored for signs and symptoms.
- Renal impairment requires dosage adjustment based on creatinine clearance to prevent drug accumulation.
- Potential for significant drug interactions exists due to fluconazole's potent inhibition of cytochrome P450 enzymes (CYP2C9, CYP3A4, and to a lesser extent CYP2C19), affecting the metabolism of numerous medications, which could lead to increased plasma concentrations and toxicity of co-administered drugs (e.
- g.
- , warfarin, phenytoin, oral hypoglycemics, benzodiazepines, statins).
- Prescribers must meticulously review a patient's medication list for potential interactions before and during fluconazole therapy.
How it Works (Mechanism of Action)
Fluconazole exerts its potent antifungal activity by selectively inhibiting fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase. This enzyme is crucial for the biosynthesis of ergosterol, which is the primary and essential sterol component of the fungal cell membrane. By blocking the 14-alpha-demethylation of lanosterol, fluconazole prevents the conversion of lanosterol to ergosterol. This inhibition leads to a cascade of events: an intracellular accumulation of 14-alpha-methyl sterols within the fungal cell membrane and a corresponding depletion of ergosterol. The altered sterol composition profoundly disrupts the structural integrity and functionality of the fungal cell membrane, increasing its permeability and ultimately leading to leakage of intracellular components essential for fungal viability. This disruption impairs vital cellular processes, inhibits fungal growth, and can lead to cell death. While often considered fungistatic, meaning it inhibits growth rather than directly killing the fungus, fluconazole can exhibit fungicidal activity against certain susceptible organisms, particularly at higher concentrations or against highly susceptible strains. Its high specificity for fungal P450 enzymes over mammalian P450 enzymes contributes to its relatively favorable safety profile compared to some other azoles, although interactions with human P450 systems do occur, leading to drug interactions.